Medpace Holdings Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Medpace Holdings Inc in the third quarter 2026?
Medpace Holdings Inc achieved a return on average equity (ROE) of 99.76 % in its third quarter 2026, this is above MEDP's average return on equity of 40.67%.
Medpace Holdings Inc shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $519 million

ROE fell compared to the second quarter 2026, despite the net income growth of 13.26% from the second quarter 2026.

Within the Medical Laboratories industry 2 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 58 to 75.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	99.2 %	151.73 %	0.79 %	-44.39 %	-
Y / Y Net Income Change	23.69 %	34.46 %	8.09 %	15.48 %	15.25 %
Net Income (TTM) in Millions	518	492	460	451	433
Return On Equity (TTM)	99.76 %	110.15 %	120.89 %	118.82 %	91.88 %
MEDP's Total Ranking	# 75	# 58	# 28	# 70	#
Equity (TTM) in Millions	585	434	598	459	294
Seq. Equity Change	34.82 %	-27.49 %	30.33 %	56.34 %	70.37 %
Seq. Net Income Change	13.26 %	-2.02 %	-8.33 %	21.59 %	23.13 %

Back to MEDP Management Effectiveness >> MEDP's 5 Years Annual ROE >> Compare MEDP ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 3
Sector	# 18
Overall	# 75

Return On Equity Statistics
High	Average	Low
120.89 %	40.67 %	3.27 %
(Mar 31 2026)		(Mar 31 2017)

MEDP Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	459	826	559	386	953
Y / Y Equity Change	-44.39 %	47.7 %	44.66 %	-59.45 %	18.26 %
Net Income in Millions	451	404	283	245	182
Y / Y Net Income Change	11.56 %	42.99 %	15.26 %	34.93 %	25.08 %
Return On Equity	98.27 %	48.98 %	50.6 %	63.5 %	19.08 %

Back to MEDP Management Effectiveness >> MEDP's 5 Years Annual ROE >> Compare MEDP ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 98.27 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MEDP's' Return on Equity at Yahoo Finance
MEDP's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MEDP's Competitors
Subscribers only: Roe for Medpace Holdings Inc 's Suppliers
Subscribers only: Return On Equity for MEDP's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Elutia Inc	267.71 %
Alnylam Pharmaceuticals Inc	159.72 %
Amneal Pharmaceuticals Inc	157.05 %
Sanuwave Health Inc	142.86 %
Arbutus Biopharma Corp	129.13 %
Alector Inc	112.21 %
Medpace Holdings Inc	99.76 %
3m Company	93.07 %
Exelixis Inc	85.83 %
Amgen Inc	85.59 %
Eli Lilly And Company	83.65 %
Rigel Pharmaceuticals Inc	73.94 %
Idexx Laboratories Inc	71.18 %
Tenet Healthcare Corp	57.13 %
Aurinia Pharmaceuticals Inc	51.92 %
Nurix Therapeutics Inc	49.34 %
Carlisle Companies Incorporated	44.18 %
Bristol myers Squibb Company	43.83 %
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %
Protalix Biotherapeutics inc	30.74 %
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %

Date modified: 2026-10-23T06:26:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.